5-Year control and treatment of edema and increased capillary filtration in venous hypertension and diabetic microangiopathy using O-(beta-hydroxyethyl)-rutosides: a prospective comparative clinical registry.
This independent prospective controlled trial evaluates the efficacy of O-(beta-hydroxyethyl)-rutosides (HR) during 5 years of administration against signs and symptoms and further degeneration of microcirculatory disturbances. The protective effect of HR in preventing end-point complications such as venous ulceration is evaluated. This study is based on evaluation of edema and the capillary filtration rate (CFR) in association with a clinical score scale. Patients having a severe degree of chronic venous insufficiency (CVI) and venous microangiopathy and completing at least 5 years of treatment are included. The following 4 groups are considered: group A (patients with CVI but without diabetes mellitus, receiving 1500 mg/d of HR), group B (patients with CVI and diabetes mellitus, receiving 2 g/d of HR), group C (control subjects receiving no pharmacologic or compression treatment), and group D (patients using elastic compression stockings only). All patients received the "best" available treatment. No adverse effects or intolerance is noted, with good compliance (>85%). In group A, there is a statistically significant decrease in the CFR during 5 years of follow-up. In group B, the decrease in the CFR is greater than that in group A. Reductions in edema, swelling, and the CFR during 5 years are notable, and values approach normal levels. During 5 years, HR is effective in treating venous edema and hypertension and in preventing deterioration of the distal venous system. The prevention of ulcerations with HR is another important observation. The effects of HR seem to be partially dose related, and tolerability and compliance are good.
Belcaro
Gianni
G
Department of Biomedical Sciences, Chieti-Pescara University, and the San Valentino Vascular Screening Project, Italy. Cardres@abol.it
Cesarone
Maria Rosaria
MR
Ledda
Andrea
A
Cacchio
Marisa
M
Ruffini
Irma
I
Ricci
Andrea
A
Ippolito
Edmondo
E
Di Renzo
Andrea
A
Dugall
Mark
M
Corsi
Marcello
M
Marino Santarelli
Anna Rita
AR
Grossi
Maria Giovanna
MG
D000284:Administration, Oral; D000328:Adult; D001783:Blood Flow Velocity; D001785:Blood Gas Monitoring, Transcutaneous; D002199:Capillary Permeability / Q000187:drug effects*; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D003925:Diabetic Angiopathies / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004487:Edema / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D006896:Hydroxyethylrutoside / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017078:Laser-Doppler Flowmetry; D008875:Middle Aged; D010349:Patient Compliance; D011446:Prospective Studies; D012042:Registries; D012720:Severity of Illness Index; D012867:Skin / Q000098:blood supply; D053828:Stockings, Compression; D013997:Time Factors; D016896:Treatment Outcome; D014689:Venous Insufficiency / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D014690:Venous Pressure / Q000187:drug effects
D002317:Cardiovascular Agents; D006896:Hydroxyethylrutoside; C005865:troxerutin